AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02747329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme™ stent
Study NCT02747329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V/Prime stent
Study NCT02161081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial CT perfusion
Description: Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
Study NCT03379532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI-NMES
Description: From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
Study NCT02691910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
Study NCT02691910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
Study NCT02691910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
Study NCT00070109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV
Study NCT00070109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03280199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation types
Description: Different types of simulation interfaces and image acquisitions
Study NCT03529838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
Study NCT03402360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality rehabilitation group
Description: Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training
Study NCT03402360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group rehabilitation
Description: Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training
Study NCT00460525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: 3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
Study NCT00460525 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
Study NCT01329068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual consult
Description: regular individual consultations
Study NCT01329068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group medical consult
Description: group medical consult
Study NCT03993119 — intervention group
Intervention type: DRUG
Intervention: Non-vitamin K antagonist oral anticoagulant
Description: Non-vitamin K antagonist oral anticoagulant
Study NCT01733524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pet Fish
Description: Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
Study NCT01733524 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Picture of a fish
Description: Participants will receive a picture of a betta fish.
Study NCT03834480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Sacroiliac intra-articular injection
Description: At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
Study NCT03868150 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Rapid Atrial Pacing
Description: Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
Study NCT03136965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Injection of autologous platelet rich plasma (PRP)
Study NCT03136965 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dry Needling
Description: This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
Study NCT03136965 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry Needling - Sham
Description: This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
Study NCT03529838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combined exercise
Description: The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
Study NCT02374281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose sucking
Study NCT02374281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water sucking
Study NCT02374281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No sucking
Study NCT03213132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Health Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study NCT03213132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHUTi (Sleep Health Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study NCT03213132 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient Education
Description: Educational website containing information on insomnia
Study NCT03652766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily Weight Tracking
Description: Daily weight tracking + weekly email or text message feedback
Study NCT04234009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle.
Study NCT00631124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4891 (Estradiol / Drospirenone)
Description: Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
Study NCT00631124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4891 (Estradiol / Drospirenone)
Description: Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
Study NCT03379532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-NMES
Description: Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
Study NCT01020227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Therapies Intervention
Description: Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
Study NCT03487068 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The FibroScan device
Description: The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
Study NCT01804075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
Study NCT02667236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 Solution
Description: Active Drug
Study NCT02667236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Placebo
Study NCT02249091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
Study NCT01804075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
Study NCT01839851 — intervention group
Intervention type: DRUG
Intervention: Treatment with any inhaled corticosteroid
Description: Use of any inhaled corticosteroid (daily frequency and dose will be registered)
Study NCT01839851 — intervention group
Intervention type: DRUG
Intervention: Treatment with any intranasal glucocorticoid
Description: Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
Study NCT02249091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
Study NCT01942330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Natural Orifice Surgery
Description: Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
Study NCT03602183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
Study NCT02249091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
Study NCT03483779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills
Description: Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
Study NCT03483779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills
Description: Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
Study NCT05792982 — intervention group
Intervention type: BEHAVIORAL
Intervention: 12 hour fasting for 29 days
Description: This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
Study NCT03602183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Description: intubation will be performed using Miller laryngoscope
Study NCT03602183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC EMS
Description: intubation will be performed using McGrath MAC EMS video - laryngoscope
Study NCT03602183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: intubation will be performed using GlideScope video - laryngoscope
Study NCT01941121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage to PrEP or Care
Description: Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
Study NCT02452489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
Study NCT04146038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT04146038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT04146038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Given PO
Study NCT04146038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02452489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
Study NCT02452489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50%whey-50% casein (Standard)
Description: see arm description
Study NCT03394651 — intervention group
Intervention type: DRUG
Intervention: Oral medications to treat lower urinary tract symptoms
Description: Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
Study NCT02419586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bubble gum
Description: Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
Study NCT02793804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oraquick (made in Thailand)
Study NCT03394651 — intervention group
Intervention type: PROCEDURE
Intervention: Minimal invasive transurethral prostate procedures
Description: Patients in this group will receive surgical treatment.
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50%whey-50% casein (Alternative)
Description: see arm description
Study NCT01326091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperlordotic Positioning
Description: Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
Study NCT01252160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: Cutaneous patch
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate- WPH
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate - Na-caseinate
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate
Description: see arm description
Study NCT02579421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: generic progesterone
Study NCT02579421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01318135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
Study NCT01318135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
Study NCT01318135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT milk
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recombined milk
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recombined 50%whey milk
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-caseinate
Description: see arm description
Study NCT03313791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein isolate
Description: see arm description
Study NCT02878746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic mirror therapy
Description: 2-dimensional
Study NCT02878746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mirror therapy
Description: 2- and 3-dimensional
Study NCT02201134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane